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ABSTRACT 
Objective: The present study was planned to explore safer, innovative and economic Angiotensin-converting enzyme inhibitors (ACEi) from beef 
extract by the action of a proteolytic Micrococcus luteus. Cytotoxicity of the stable peptide was predicted using MCF-7 cell line in vitro. 
Methods: ACEi was purified by sequential steps of ethanol precipitation, ion exchange column chromatography (MonoQ) and gel filtration column 
chromatography (Sephadex G25). The apparent molecular mass was determined by SDS-PAGE. The anticancer property was analyzed by studying 
the cytotoxicity effects of angiotensin converting enzyme inhibitor using Breast cancer MCF-7 cell lines 
Results: The peptide was purified and molecular mass was determined as 4.5 kDa. The IC50 value of peptide was found to be 59.5 µg/ml. The DNA 
fragmentation was not observed in the treated cells. The purified peptide has demonstrated to induce apoptosis of cancer cell. The results proved 
that the peptide has the ability to be used for cancer therapy. 
Conclusion: The presence of ACE inhibition activities in the fermentation of beef extract using Micrococcus luteus has been investigated. The 
Peptide has been determined as an active compound that inhibited the activity of ACE. These properties indicate the possibilities of the use of 
purified protein as a potent anticancer agent. 
Keywords: Angiotensin-converting enzyme inhibitors, Micrococcus luteus, Anti-proliferative, Anti-metastatic, MCF-7 cell line, Anticancer activity. 
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INTRODUCTION 
Angiotensin-converting enzyme (ACE) is a dipeptide hydrolase that 
catalyses both the formation of the potent vasoconstrictor, 
angiotensin-II (Ang II), and the deactivation of bradykinin, a 
vasodilator peptide. Given the potential of Angiotensin II in 
containing the proliferation of the tumour, production of these 
inhibitors by bacteria could open new doors for anticancer therapy. 
The protective effect of ACEi cannot be attributed solely to the 
inhibition of AngII production. Rather, multiple mechanisms that are 
not yet fully understood could be responsible for the same. ACEi has 
also been reported to suppress vascular endothelial growth factor 
(VEGF), which is believed to play a major role in stimulating 
angiogenesis in human growth [1]. Although genotypic studies on 
ACE and the risk of cancer in humans have yielded contradictory 
results, the use of ACE inhibitors in experimental animal models has 
consistently indicated a protective effect of these drugs against 
tumor development. Perindopril, a well known ACEi used either 
alone or in combination with β interferon, was found to inhibit VEGF 
expression, endothelial cell migration and tubular formation in 
matrigel, thus proving its role in protection against tumor 
angiogenesis [2, 3]. Captopril, yet another ACEi, was also observed to 
attenuate tumor growth and angiogenesis of syngeneic fibrosarcoma 
when injected in rats [4].  
In the recent years, several studies have identified peptides to act as 
inhibitors against ACE activity. ACE-inhibitory peptides have been 
discovered, isolated and purified from enzymatic hydrolyzates of 
different food proteins. Physiological and pharmacological effects of 
ACE inhibitory peptides derived from food proteins and their 
prospective applications in preventing hypertension, cancer and for 
therapeutic purposes have also been reported [5]. Various bioactive 
peptides including ACE-inhibitory or antihypertensive peptides, 
immunomodulatory, antioxidative, antimutagenic, anticancer 
peptides have been released from milk proteins, eggs, meat and fish 
as well as in different plant protein sources such as soy and wheat 
through microbial proteolysis [6-8]. The choice of the strain, which 
influences the release of effective bioactive peptides, is one of the 
most effective ways of increasing the concentrations of bioactive 
peptides. Hence, it is imperative that the strain does not exhibit 
proteolytic properties, failing which the product will be destroyed. It 
is also important that the strain has the right specificity to produce a 
higher concentration of bioactive peptides. The concentration of 
ACE-inhibitory peptides seems to rely on a balance between the 
formation of bioactive peptides and its consequent breakdown into 
inactive peptides and amino acids, which in turn depend on storage 
time and conditions. 
With the exception of Lactobacillus delbrueckii and Lactobacillus 
lactis which are used for milk fermentation, the uses of microbes as 
ACE inhibitor source have been less explored. Edible mushrooms 
Tricholoma giganteum have also been proved to have ACE inhibiting 
peptide. Many research groups have combed for ACE inhibitors in 
microbial sources such as Doratomyces putredinis, Nocardia 
orientalis, Streptomycetes, Actinomycetes, Actinomadura, 
Spiculospora and Actinomadura [9]. Based on these findings, this 
research focuses on isolating and identifying ACE inhibitor from the 
fermentation of beef extract using Micrococcus luteus.  
MATERIALS AND METHODS  
Microorganism and crude enzyme preparation 
The isolated strain Micrococcus luteus (GenBank accession number 
Kf303592.1) was inoculated into a protease specific medium broth 
containing Beef extract (2.0 g/l), MgSO4.7H2O (0.1482 g/l), KH2PO4 
(0.3 g/l), FeSO4.7H2O (0.003 g/l), Na2HPO4 (1.28 g/l), NaCl (0.05 g/l), 
NH4Cl (0.1 g/l), Thiamine (0.03 g/l), CaCl2.2H2O (0.0456 g/l). The 
inoculated broth was incubated at 37 °C for 1 d in an orbital shaker 
at 150 rpm. After fermentation, the entirely fermented broth was 
extracted, and the clear supernatant was recovered. The supernatant 
was filtered through a 0.45 mm cellulose acetate filter paper [10]. 
The crude enzyme extract was further subjected to the purification 
process. Before purifying the protein content [11], the ACE 
inhibitory activity of the crude extract was estimated. 
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Measurement of ACE inhibitory activity  
The ACE inhibitory activity was assayed by the method of Cushman 
and Cheung [12] with a few modifications. Hip-His-Leu (HHL) was 
dissolved in 50 mM sodium borate buffer (pH 7.0) containing 1 N 
NaCl. Following this, 25 μl of 5 mM (HHL) solution was mixed with 
10 μl of beef hydrolysate (the pH of which was adjusted to 7.0) and 
then pre-incubated for 10 min at 37 °C. The reaction was initiated by 
adding10 μl of ACE and the mixture was incubated for 30 min at 37 
ºC. The reaction was stopped by adding 200 μl of 1 N HCl. The 
hippuric acid liberated by ACE was extracted with 1 ml ethyl acetate, 
dissolved by adding 1 ml of the buffer after the removal of ethyl 
acetate by vacuum evaporation, and the optical density was 
measured at 228 nm. The extent of inhibition was calculated using 
the formula  
 
Result expressed in percentage 
Where, A = the optical density in the presence of ACE and ACE 
inhibitory component; B = the optical density without an ACE 
inhibitory component; C = the optical density without ACE. 
Purification of ACE inhibitory peptide 
The crude extract of fermented medium with the selected substrate 
by test strain was extracted with three volumes of chilled ethanol. 
The pellet was suspended in Tris-HCl (20 mM; pH 7.0) and further 
purified by ion exchange column chromatography (Mono Q) and by 
size exclusion chromatography (Sephadex G25). Each fraction was 
then tested for ACE inhibition activity and protein content. The 
protein profile of the active fraction with ACE inhibition was studied 
using 15% sodium dodecyl sulfate-polyacrylamide gel electro-
phoresis (SDS-PAGE) and the molecular weight of the protein was 
also determined.  
SDS-page profile 
The apparent molecular weight of the peptide was determined by 
SDS-PAGE with proteins of known molecular weight along with the 
protein to be characterized [13] in 15% polyacrylamide gel with a 
modified protocol [14]. 
Cytotoxicity of ACE inhibitor on breast cancer cell Line  
Cell line and culture 
Breast cancer MCF-7 cell lines used in this study were obtained from 
King Institute of Preventive Medicine and Research, Chennai, India. 
The cells were maintained in Minimal Essential Media (MEM) 
supplemented with 10% FBS, penicillin (100 U/ml), and 
streptomycin (100 μg/ml) in a humidified atmosphere of 50 μg/ml 
CO2 at 37 °C.  
Preparation of ACE inhibitor  
ACE inhibitor was prepared by fermenting the beef extract by 
Micrococcus luteus. The ACE inhibitor was purified by a series of 
steps namely ethanol precipitation, ion exchange column 
chromatography and gel filtration column chromatography. The 
purified fraction in Tris-HCl buffer (pH 7.0, 20 mM) with the protein 
content of 1 mg/ml was used for cytotoxicity analysis. Various 
concentrations of the ACE inhibitor were then analyzed for 
cytotoxicity activity.  
In vitro anticancer study  
Breast cancer MCF-7 cell lines obtained from King Institute of 
Preventive Medicine and Research, Chennai, India was used for the 
present study. The Breast cancer cells were grown in Eagles 
Minimum Essential Medium (EMEM) containing 10% fetal bovine 
serum (FBS). For screening experiments, the cells were seeded into 
96-well plate in 100 μl of medium containing 5% FBS, at a plating 
density of 10,000 cells/well. These cells were then incubated at 37 
ºC, 5% CO2, 95% air and 100% relative humidity for 24 h prior to the 
addition of ACEi. ACEi in 20 mM Tris buffer (pH, 7.0) was diluted in 
serum-free medium. After 24 h incubation, 100 μl of the medium 
containing the ACEi at various concentrations (1000 µl, 500 µl, 250 
µl, 125 µl, 62.5 µl, 31.2 µl, 15.6 µl and 7.8 µl/ml) were added and 
incubated at 37 °C, 5% CO2, 95% air and 100% relative humidity for 
48 h. Triplicate was maintained and simultaneously a control was 
kept without the addition of ACE inhibitor. 
Anticancer activity  
The effect of ACE inhibitor on MCF-7 cell viability was determined by 
MTT [3-(4,5-Dimethyl-thiazol-2-yl)-2,5-Diphenyltetrazolium bromide] 
assay [15]. The yellow tetrazolium salt of MTT was reduced by 
mitochondrial dehydrogenases in metabolically active cells to form 
insoluble purple formazan crystals. These crystals were solubilized 
by the addition of a detergent. Cells (1 × 105 cells/well) were 
incubated with various concentrations of the compound at 37 ºC for 
48 h in an FBS-free medium, before being subject to MTT assay. The 
absorbance at 570 nm was measured using UV Spectrophotometer. 
The relative cell viability was determined by the amount of MTT 
converted to the insoluble formazan salt. The data have been 
expressed as the mean percentage of viable cells and compared with 
respective to control. The half maximal growth inhibitory 
concentration (IC50) values were calculated.  
DNA fragmentation assays by agarose gel electrophoresis  
The degradation of DNA into multiple fragments of 39 to 41 base 
pairs is a distinct biochemical hallmark of apoptosis. DNA 
fragmentation was analyzed by agarose gel electrophoresis of 
genomic DNA extracts from the Breast cancer MCF-7 cell lines 
treated with 20 μl of ACE inhibitor for three hours. The DNA was 
visualized by placing the gel on a UV transilluminator [16].  
RESULTS AND DISCUSSION 
In earlier reports, intense proteolysis by endogenous muscle 
enzymes resulted in an accumulation of peptides [17-19] and free 
amino acids at the end of the dry-curing process of meat [20, 21]. 
Similarly, ACE inhibitory peptides were identified in muscle tissues 
after hydrolysis of pork meat [22, 23] or derived in vitro from the 
digestion of pork meat [24]. In an earlier study, water-soluble 
fraction of Spanish dry-cured ham was also found to exhibit 
antihypertensive activity both in vivo in spontaneously hypertensive 
rats (SHR) and in vitro ACE inhibitory activity [25]. Based on these 
findings and observations, in the present study beef extract was 
used as a substrate for hydrolyzing using Micrococcus luteus.  
Purification of ACE inhibitory peptides 
Crude extract of the fermented beef extract was found to have 
78.55±0.42% ACE inhibition and protein content was determined to 
be 8.66 mg/ml. In the present study, the peptides were concentrated 
using ethanol precipitation. 
Ion exchange chromatography is being widely used at the beginning 
of a purification scheme and is designed for separating ionic or 
ionizable compounds in the mobile phase by the counter-ion of the 
opposite sign in the stationary phase (column packing) [26]. Among 
the fixed stationary phase, diethyl aminoethyl (DEAE) is being 
extensively used in the conventional anion exchange chromato-
graphy during ACEIP purification [27-30]. Ion Exchange was used to 
purify hydrolyzate from seaweed pipefish muscle and obtained the 
reasonable IC50 value [29]. Hiprep 16/10 DEAE ion exchange column 
was used to purify the hydrolyzate of salmon pectoral fin [27]. They 
found that the purified hydrolyzate provided on an IC50 at a 
concentration of 169 μg/ml after passing through the column and 
decreased around three times when compared to the native 
hydrolyzate (IC50 = 365 μg/ml). In the present study, the strong 
anion exchange Mono Q column was used. The soluble crude protein 
extract was dissolved in a minimal volume of 20 mM Tris-HCl buffer 
pH 7 and fractionated on Mono Q column. After washing the 
unbound protein with 20 mM Tris-HCl buffer, the column-bound 
protein was eluted with 100 ml linear salt gradient (0-100 mM NaCl 
in 20 mM Tris-HCl, the flow rate was 3 ml/min). The active fraction 
(Fraction 39 to 41, fig. 1) which displayed ACE inhibitory activity 
were pooled, dialyzed against 20 mM Tris-HCl and was taken for 
Sephadex G25 chromatography. The protein content of the pooled 
Upon precipitation the ACE inhibition 
was 74.96±0.85% and protein content was observed to be 4.00 
mg/ml.  
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fractions was observed to be 0.92 mg/ml (table 1). The ACE 
inhibition of the active fraction was observed to be 84.22±0.79%. It 
is a known fact that the strong anion exchange column tends to bind 
tightly to the positively charged molecules and release only at a 
higher concentration of NaCl. Hence, in the present study, the active 
fractions which were eluted at higher NaCl gradient (~70%) 
revealed that the peptides may be highly positively charged.  
The pooled fractions were further purified on a Sephadex G25 
column and eluted with 20 mM Tris-HCl buffer containing 100 mM 
NaCl. The chromatogram showed three peaks (fig. 2). The fractions 
(111 to 113) under the highest peak were found to have an ACE 
inhibitory activity which was pooled and checked for purity. The 
protein content of the purified fraction was observed to be 0.4 mg/ml 
with ACE inhibition of 85.43±1.08%. Similar results from earlier work 
after peptide fractionation through size-exclusion chromatography 
[25] revealed that the strongest ACE inhibitory activity (85% of ACE 
inhibition) was obtained from eluted fractions. It may be assumed that 
the peptides with a lower molecular weight exhibit a higher molecular 
mobility and diffusivity when compared to these peptides with a 
higher molecular weight, which appears to improve interactions with 
cancer cell components and enhances anticancer activity [31]. A study 
on the mechanism of action revealed that the modulation of 
hydrophobicity of peptides plays a crucial role against cancer cells 
[32]. In the purification process during Ion exchange chromatography 
using Mono Q column, a strong anion exchange column, the peptides 
were eluted only at higher NaCl concentration could be attributed to 
its higher positive charges. This positive charge and hydrophobicity 
might not only impart the ACE inhibitory activity but would also 
facilitate higher interaction with cancer cells as reported earlier. 
Electrophoretic analysis of ACE inhibitory peptide 
On SDS-PAGE analysis using 15% gel, several bands were found to 
appear in the crude extract (lane 1 & 2 of Fig.3), confirming the 
presence of unwanted impurities. Thus, warranting further 
purification. The fractions (fractions 39 to 41) of ion exchange 
column (lane 5, 7 & 8 of Fig.3) showed three prominent bands. The 
purified fractions of gel filtration column (lane 4 of Fig.3) showed a 
single band. The apparent molecular weight was found to be around 
4.5 kDa. The size of the generated peptides is crucial to the ACE 
inhibitory effect as previously reported [33, 34]. The peptides with 
lower MW were easily absorbed compared to peptides with higher 
MW [35]. In agreement to the earlier report the peptides of smaller 
molecular weight seem to exhibit ACE inhibitory activity. 
Sarcoplasmic and myofibrillar porcine proteins are hydrolyzed by 
the action of Lactobacillus sakei CRL 1862 and L. curvatus CRL 705 
[36]. They were successful in generating ACE inhibitory peptides by 
fermentation. It has been reported that muscle foods served as an 
interesting substrate for producing potential bioactive peptides. 
Earlier marine proteins from shrimp when fermented with L. 
fermentum SM 605 was found to yield three ACE inhibitor peptides 
[37]. These reports confirm the ACE inhibitory peptides were 
produced by microbial hydrolysis which further supports the 
findings of the present study.  
As stated earlier, the mode of action of the majority of ACE inhibitory 
peptides proves to be competitive substrates for ACE. Most 
  
ACE 
inhibitory peptides found in meat can be classified as true inhibitor 
type peptides [23, 38, 39]. These peptides may act in one of the two 
ways: first the peptide may bind to the active site of the ACE enzyme, 
or it may bind to an inhibitor site located on the ACE, thus modifying 
the protein conformation and preventing the substrate (Ang І) from 
binding to the enzyme active site [40]. 
 
Fig. 1: Ion exchange column chromatogram of ACE inhibitory peptide 
 
 
Fig. 2: Size exclusion column chromatogram of ACE inhibitory peptide 
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Fig. 3: SDS-PAGE profile of ACE inhibitory peptide purification process 
 
Lane 1,2,3–Crude extract; Lane 4–Protein fraction of sephadex G25 
column (size exclusion chromatography); Lane 5,7,8,–Protein 
fraction of ion exchange column; Lane 9–Molecular Weight Markers 
(26.6, 17, 14.2, 6.5, 3.496, 1.06 kDa). 
 
Table 1: Purification table of ACE inhibitory peptide 
S. No. Purification step Volume (ml) Protein content (mg/ml) ACE inhibition (%) 
1 Crude extract 2000 8.66 78.55±0.42 
2 Ethanol precipitation 50 4.00 74.96±0.85 
3 Ion exchange column (fraction 39-41) 6 0.92 84.22±0.79 
4 Size exclusion column (Fraction 111-113) 6 0.40 85.43±1.08 
The experiment was done in triplicates and the values of ACE inhibition (%) expressed as mean±SD.  
 
In vitro anticancer analysis 
The peptide isolated in the present study was observed to have a 
cytotoxic effect on the MCF-7 cell line. The IC50 value of the peptide 
was determined to be 59.5 µg/ml. The cytotoxic effect was found to 
have a linear relation with the concentration of the peptide, which 
explains the sequential reduction in viability percentage of cancer 
cells (MCF-7 cell line) in the graph (fig. 4). The control cells which 
were not treated with ACE inhibitor were observed to be elongated 
and proper confluence growth was observed (fig. 5). The cell after 
treatment with ACE inhibitor were seen as round shaped which 
confirmed the detachment of the cells from the surface. These 
rounded cells were indicators of apoptotic cells. The cells treated 
with 62.5 µg/ml were found to be mostly rounded and as the 
concentration of ACE inhibitor was increased further the total cell 
count itself was observed to be reduced (fig. 5).  
Oyster hydrolyzates inhibited tumor growth by improving the 
immune function in S108-bearing mice, which suggested their 
potential use in tumor therapy [41]. An enzymatic hydrolyzate from 
jumbo squid skin gelatin showed a cytotoxic effect against MCF-7 
and U87 cell lines, with IC50 values of 0.13 and 0.10 mg/ml, 
respectively [42]. Solitary tunicate hydrolyzate was reported to 
show potent anticancer activity against AGS, DLD-1, and HeLa cancer 
cells. However, the anticancer activities of these fractions (IC50 
577.1–1240.0 μg/ml) were found to be much higher than that of the 
commercial standards such as Paclitaxel (IC50 2.2–24.6 μg/ml) and 
5-Flurouracil (IC50 3.4–34.5 μg/ml) [32]. 
An appropriate inhibition of Ang II production by ACE inhibition was 
found to inhibit proliferation via AT1 receptor and calcium channel 
blockade. ACE inhibition promotes apoptosis in vascular smooth 
muscle cells [43, 44]. The combined effect of perindropril and IFN 
proved to induce epithelial cell apoptosis and secondary apoptosis of 
the tumor cells by attenuating the expression of VEGF [45]. Similarly, 
the apoptotic activity of the peptides from beef extract fermented by 
bacteria in the present study could also be attributed to the ACE 
inhibitory activity of the extract.  
Apratoxin A is cyclic depsipeptide extracted from Lyngbya majuscula 
which exhibited cytotoxic effects on human HeLa cervical carcinoma 
cells by cell cycle inhibition [46]. A similar mechanism has been 
observed by cyclic depsipeptide Coibamide A which was isolated 
from Leptolyngbya sp. Human lung cancer cell line [47] and 
Lyngbyabellin B isolated from Lyngbya majuscula on human Burkitt 
lymphoma cells [48]. Linear Pentapeptide Dolastatin 10 and 
Symplostatin 1 were isolated from Symploca sp. which exhibited a 
cytotoxic effect on human lung cancer cell line and human breast 
carcinoma cell line by both Bcl-2 phosphorylation and Caspase-3 
protein activation [49, 50]. Besides, there were also different types 
of anticancer peptides isolated from Lyngbya sp. and Nostoc sp, 
which exhibited inhibiting activity against cancer on different cell 
lines through microfilament disruption, secretory pathway 
inhibition, etc [51, 52].  
The peptide transporters viz. PEPT1 and PEPT2, in mammals, are 
being investigated for peptide-based delivery systems. These 
transporters are integral plasma membrane proteins that mediate 
the cellular uptake of di and tri peptides and peptide-like drugs. 
They are present predominantly in epithelial cells of the small 
intestine, bile duct, mammary glands, lung, choroid plexus and 
kidney, but are also localized in other tissues (Pancreas, liver, 
Gastrointestinal tract). Intriguingly, they seem to be overexpressed 
in some types of tumors but not in their corresponding healthy 
tissues [53, 54]. These peptide transporters act as Trojan horses 
facilitating the delivery of pharmacologically active compounds due 
to their wide substrate binding capacity (bind molecules with 
different size, hydrophobicity and charge [55]. This peptide 
transporter delivery system is an added advantage for the peptides 
to be delivered to the cancer cells without imparting any negative 
effects on the healthy cells. 
In the present study, the DNA laddering assay revealed that the 
peptides induced DNA fragmentation was not clearly seen in the 
agarose gel pattern of DNA from treated cells (fig. 6). Even though an 
earlier report [48] stated that the ACE inhibitor produce DNA 
fragmentation, there are several reports which suggest cell death by 
an alternate mechanism as well Didemnin depsipeptides were 
reported to have a cytotoxic effect on cancer cell lines by inhibiting 
protein synthesis in vitro [56]. The peptide was supposed to inhibit 
protein synthesis by ribosome-EF-1α complex, as a correlation 
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between inhibiting protein synthesis in cell lysates and in human 
adenocarcinoma MCF-7 cells was observed [57]. Studies with 
Jaspamide in HL-60 human leukemia cell line revealed that the 
nanomolar concentrations of this depsipeptide inhibited cell 
proliferation and also increased polynuclear cells [58]. In yet 
another study, Cryptophycin-52, a member of the family of the 
marine depsipeptides-Cryptophycins, produced by total chemical 
synthesis, showed antitumor activity at picomolar concentrations. 
This compound was found to exhibit anti-proliferative activity by 
stabilizing spindle microtubules, and by binding tightly and non-
covalently to a single high-affinity site on tubulin while also inducing 
a conformational change in the tubulin molecule [57, 59]. ACE 
inhibitors were also reported to have antioxidant properties [60]. In 
view of these earlier reports, the peptide isolated in the present 
study might have induced cytotoxicity by any one of the mechanisms 
without involving DNA fragmentation.  
Studies on peptides obtained from protein hydrolyzates have shown 
that these biomolecules contain antioxidant, antiproliferative, and 
antimutagenic activities which could confer on them anticancer 
properties. In agreement with the earlier reports, the peptide isolated 
in the present study from beef extract could exhibit anticancer activity 
through not only the ACE inhibition pathway but also through other 
pathways already reported. However, the effects of the 
antiproliferative peptides on cell cycle of normal and transformed cells 
and, on the structure of the bioactive peptides, and in vivo studies of 
these activities need to be investigated further. Nevertheless, there is a 
need for scaled-up production of these compounds, which could be 
achieved by the utilization of microbial by-products. 
 
 
Fig. 4: Cytotoxicity of ACE inhibitor showed the viability 
percentage of cancer cells (MCF cell line) 
 
 
Fig. 5: Cytotoxicity effect of ACE inhibitor on breast cancer cell 
line MCF-7 
A: MCF-7 control cells untreated with an ACE inhibitor; B: MCF-7 
cells treated with 62.5 µg/ml of ACE inhibitor; C: MCF-7 cells treated 
with 125 µg/ml of ACE inhibitor; D: MCF-7 cells treated with 250 
µg/ml of ACE inhibitor 
 
 
Fig. 6: DNA fragmentation of MCF-7 cells treated with an ACE 
inhibitor M-Marker1000bp (base pairs) DNA ladder; L1-l; L2-
250µg/ml; L3-125µg/ml; L4-62.5µg/ml 
 
CONCLUSION 
The presence of ACE inhibitory peptide in beef extract fermented by 
Micrococcus luteus was investigated. The present study succeeded in 
isolating and purifying a potent ACE inhibitor by ethanol 
precipitation followed by ion exchange chromatography and size 
exclusion chromatography. The molecular weight of the ACEi was 
determined to be around 4.5 kDa. The anticancer property was 
analyzed by studying the cytotoxic effect of the purified ACEi on 
MCF-7 cell lines and the IC50 value of the peptide was found to be 
59.5 µg/ml. This property enthuses to explore further the 
possibilities of the purified ACEi as a potent anticancer agent. 
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